ARTICLE | Financial News
Cidara raises $42M in series B
February 12, 2015 2:23 AM UTC
Infectious disease company Cidara Therapeutics Inc. (San Diego, Calif.) raised $42 million in a series B round from undisclosed new and existing institutional investors.
Cidara expects to start a Phase I trial in 2H15 of lead candidate biafungin, an echinocandin antifungal, to treat systemic Candida infections. The company also plans to start a Phase Ib/II trial of topifungin, a topical version of biafungin, in 2H15. ...